ArticleDiscover oncology2025
Exploring the relationship between hypoxia in lung adenocarcinoma and tumor microenvironment immune cell infiltration.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe hypoxic microenvironment affects the development of many types of tumors. It also triggers a series of immune response, and affects the level of immune cells infiltration. Here, the study aims to develop a gene marker based on hypoxia for prognosis evaluation in lung adenocarcinoma (LUAD), and investigate the relationship between hypoxia and immune cell infiltration in the tumor microenvironment (TME).
methodRetrieving LUAD cases from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. Through bioinformatics analysis, we screened out the hypoxia genes correlated with the prognosis of LUAD. A hypoxia risk score model was established by using gene expression level and expression coefficient. Using the median risk score value, we divided the patients in the two databases into high-risk and low-risk groups. The hypoxic model was then validated using survival analysis and receiver operating characteristic (ROC) curves. The CIBERSORT calculation method was employed to analyze the infiltration of immune cells. Finally, we analyzed the correlation between immune genes and hypoxia.
resultPatients in the high-risk group, characterized by higher hypoxia risk scores, exhibited significantly poorer prognosis compared to those in the low-risk group. In addition, we found significant differences in the infiltration rates of these five types of immune cells (M0 macrophages, M1 macrophages, resting mast cells, activated mast cells, monocytes, resting NK cells and activated CD4
conclusionWe discovered that the hypoxia risk score was related to prognosis and immune cell infiltration rate of LUAD. This finding may provide new ideas for LUAD immunotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.